Kingkan Bunluepeuch

Dr. Kingkan Bunluepeuch


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in Heliyon
Verified
Journal Article
Open access
KEKomgrit Eawsakul
Komgrit Eawsakul
PPPharkphoom Panichayupakaranant
Pharkphoom Panichayupakaranant
TOTassanee Ongtanasup
Tassanee Ongtanasup
Sakan WarinhomhounSakan Warinhomhoun
Sakan Warinhomhoun
KNKunwadee Noonong
Kunwadee Noonong
KBKingkan Bunluepeuch
Kingkan Bunluepeuch
The number of patients with type 2 diabetes mellitus (T2DM) has increased worldwide. Although an instant cure was achieved with the standard treatment acabose, unsatisfactory symptoms associated with cardiovascular disease after acabose administration have been reported. Therefore, it is important to explore new treatments. A Thai folk recipe has long been used for T2DM treatment, and it effectively decreases blood glucose. However, the mechanism of this recipe has never been proven. Therefore, the potential anti-T2DM effect of this recipe, which is used in Thai hospitals, was determined to involve alpha-glucosidase (AG) inhibition with a half maximal inhibitory concentration (IC50). In vitro experiments showed that crude Cinnamomum verum extract (IC50 = 0.35 ± 0.12 mg/mL) offered excellent inhibitory activity, followed by extracts from Tinospora crispa (IC50 = 0.69 ± 0.39 mg/mL), Stephania suberosa (IC50 = 1.50 ± 0.17 mg/mL), Andrographis paniculate (IC50 = 1.78 ± 0.35 mg/mL), and Thunbergia laurifolia (IC50 = 4.66 ± 0.27 mg/mL). However, the potencies of these extracts were lower than that of acabose (IC50 = 0.55 ± 0.11 mg/mL). Therefore, this study investigated and developed a formulation of this recipe using computational docking. Among 61 compounds, 7 effectively inhibited AG, including chlorogenic acid (IC50 = 819.07 pM) through 5 hydrogen bonds (HBs) and 2 hydrophobic interactions (HIs); β-sitosterol (IC50 = 4.46 nM, 6 HIs); ergosterol peroxide (IC50 = 4.18 nM, 6 HIs); borapetoside D (IC50 = 508.63 pM, 7 HBs and 2 HIs); borapetoside A (IC50 = 1.09 nM, 2 HBs and 2 His), stephasubimine (IC50 = 285.37 pM, 6 HIs); and stephasubine (IC50 = 1.09 nM, 3 HBs and 4 HIs). These compounds bind with high affinity to different binding pockets, leading to additive effects. Moreover, the pharmacokinetics of six of these seven compounds (except ergosterol peroxide) showed poor absorption in the gastrointestinal tract, which would allow for competitive binding to AG in the small intestine. These results indicate that the development of these 6 compounds into oral antidiabetic agents is promising.

30 January 2023 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
KEKomgrit Eawsakul
Komgrit Eawsakul
TOTassanee Ongtanasup
Tassanee Ongtanasup
NNNgamrayu Ngamdokmai
Ngamrayu Ngamdokmai
KBKingkan Bunluepeuch
Kingkan Bunluepeuch
Introduction: Bioactive compounds from traditional medicines are good alternatives to standard diabetes therapies and may lead to new therapeutic discoveries. The stems of Bauhinia strychnifolia Craib. (BC) have a possible antihyperglycemic effect; However, the extraction of astilbin from BC has never been recorded in alpha-glucosidase inhibitory activities. Methods: Using liquid chromatography–mass spectrometry (LC–MS/MS), 32 compounds were detected in the BC extract. The screening was based on peak area. Seven compounds found. PASS recognized all seven compounds as potential alpha-glucosidase (AG) inhibitors. Astilbin and quercetin 3-rhamnoside were the most likely inhibitors of AG. Arguslab, AutoDock, and AutoDock Vina investigated the binding of the two compounds and AG. The binding stability was confirmed by molecular dynamics (MD). In addition, the optimum solvent extraction was studied via CosmoQuick, and extracts were examined with 1H-NMR prior to testing with AG. Results: All three software programs demonstrated that both compounds inhibit AG more effectively than acarbose. According to the sigma profile, THF is recommended for astilbin extraction. The BC extract with THF showed outstanding AG inhibitory action with an IC50 of 158 ± 1.30 µg mL-1, which was much lower than that of the positive control acarbose (IC50 = 190 ± 6.97 µg mL-1). In addition, astilbin from BC was found to inhibit AG strongly, IC50 = 22.51 ± 0.70 µg mL-1 through the extraction method of large-scale astilbin with THF has the best extraction capacity compared to other solvents, hence the initial stage of extraction employs THF to extract and precipitate them with ethyl acetate and water. Conclusion: In silico and in vitro studies reveal that astilbin inhibits AG and is superior to acarbose, validating its promise as an AG inhibitor. Overall, astilbin was the most bioactive component of BC for antidiabetic action.

5 September 2022 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
KNKunwadee Noonong
Kunwadee Noonong
KPKanta Pranweerapaiboon
Kanta Pranweerapaiboon
KCKulathida Chaithirayanon
Kulathida Chaithirayanon
KSKantamat Surayarn
Kantamat Surayarn
PDPhicharinee Ditracha
Phicharinee Ditracha
KBKingkan Bunluepeuch
Kingkan Bunluepeuch
Background: Lysiphyllum strychnifolium (Craib) A. Schmitz, a traditional Thai medicinal plant, is mainly composed of polyphenols and flavonoids and exhibits several pharmacological activities, including antioxidant, anticancer, antimicrobial, and antidiabetic activities. However, the mechanism by which pure compounds from L. strychnifolium inhibit glucose catalysis in the small intestine and their effect on the glucose transporter remain unknown. Methods: The objectives of this research were to examine the effect of 3,5,7-trihydroxychromone-3-O-𝛼-L-rhamnopyranoside (compound 1) and 3,5,7,3’,5’-pentahydroxy-flavanonol-3-O-𝛼-L-rhamnopyranoside (compound 2) on the inhibition of α-amylase and α-glucosidase, as well as glucose transporters, such as sodium-glucose cotransporter 1 (SGLT1), glucose transporter 2 (GLUT2), and glucose transporter 5 (GLUT5), using Caco-2 cells as a model of human intestinal epithelial cells. Additionally, the binding affinity and interaction patterns of compounds against two receptor proteins (SGLT1 and GLUT2) were determined for the first time utilizing a molecular docking approach. Results: In the α-amylase inhibition assay, a concentration-dependent inhibitory response was observed against the enzyme. The results indicated that compound 1 inhibited α-amylase activity in a manner similar to that of acarbose (which exhibit IC50 values of 3.32 ± 0.30 µg/mL and 2.86 ± 0.10 µg/mL, respectively) in addition to a moderate inhibitory effect for compound 2 (IC50 = 10.15 ± 0.53 µg/mL). Interestingly, compounds 1 and 2 significantly inhibited α-glucosidase and exhibited better inhibition than that of acarbose, with IC50 values of 5.35 ± 1.66 µg/mL, 510.15 ± 1.46 µg/mL, and 736.93 ± 7.02 µg/mL, respectively. Additionally, α-glucosidase activity in the supernatant of the Caco-2 cell monolayer was observed. In comparison to acarbose, compounds 1 and 2 inhibited α-glucosidase activity more effectively in Caco-2 cells without cytotoxicity at a concentration of 62.5 µg/mL. Furthermore, the glucose uptake pathways mediated by SGLT1, GLUT2, and GLUT5- were downregulated in Caco-2 cells treated with compounds 1 and 2. Additionally, molecular modeling studies revealed that compounds 1 and 2 presented high binding activity with SGLT1 and GLUT2. Conclusion: In summary, our present study was the first to perform molecular docking with compounds present in L. strychnifolium extracts. Our findings indicated that compounds 1 and 2 reduced glucose uptake in Caco-2 cells by decreasing the expression of glucose transporter genes and inhibiting the binding sites of SGLT1 and GLUT2. Therefore, compounds 1 and 2 may be used as functional foods in dietary therapy for postprandial hyperglycemia modulation of type 2 diabetes.

1 January 2024 in Advances in Pharmacological and Pharmaceutical Sciences
Verified
Journal Article
Open access
Komgrit EawsakulKomgrit Eawsakul
Komgrit Eawsakul
KBKingkan Bunluepeuch
Kingkan Bunluepeuch
Compared with the use of a single herb alone, herb combinations can significantly increase their effectiveness in treating various diseases. The objective of this research was to determine the appropriate proportions of Garcinia mangostana (GM), Curcuma comosa (CC), and Acanthus ebracteatus (AE) to enhance their antioxidant and anti‐inflammatory properties. The study employed computer modeling (in silico) and laboratory testing (in vitro). The optimal levels of phenolic and flavonoid compounds were achieved with a ratio of 15 parts GM, 5 parts CC, and 10 parts AE. In contrast, the 10 : 15 : 5 ratio resulted in the highest antioxidant activity, reducing DPPH radicals by 80.33% and ABTS radicals by 92.20%. The ratio had a synergistic effect and was within the safe range, ranging from 82.97 to 147.04 µg/mL. The ratio of 5 : 10 : 15 had the greatest anti‐inflammatory effects, with an exceptional activity level of 98.86%. It effectively suppressed 23 genes or proteins, including the prominent NFE2L2 gene, and had a synergistic effect. This combination effectively inhibits inflammation (IC50: 12.05 µg/mL) and is safe for macrophages at concentrations up to 50 µg/mL. These findings emphasize the potential of these herbal mixtures for antioxidant and anti‐inflammatory applications.

10 July 2025 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
KEKomgrit Eawsakul
Komgrit Eawsakul
KBKingkan Bunluepeuch
Kingkan Bunluepeuch
SWSueptrakool Wisessombat
Sueptrakool Wisessombat
Acne vulgaris (AV) is a common, long-lasting skin condition characterized by inflammation that is frequently linked to the bacteria Cutibacterium acnes (C. acnes) and Staphylococcus spp. Conventional medicines face difficulties, such as bacterial resistance, in treating acne vulgaris, highlighting the need for new treatment approaches. In this study, we investigated the antibacterial activity of three medicinal plants, Garcinia mangostana (GM), Curcuma comosa (CC), and Acanthus ebracteatus (AE), which are traditionally used to treat different illnesses because of their antibacterial, antioxidant, and anti-inflammatory properties. We utilized a mix of in silico, in vitro, and molecular dynamics (MD) techniques to assess their abilities to treat skin breakouts. We found that the active ingredients in these herbs significantly interact with several bacterial and human inflammatory proteins. Specifically, the herbal components strongly bind to the bacterial enzyme topoisomerase II alpha (TOP2α), which is fundamental for bacterial DNA replication and repair, as well as to human nuclear factor kappa B subunit 1 (NFκB1), which is a vital marker of inflammation. The findings from this study suggest that this combination treatment offers two advantages, preventing bacterial growth and reducing inflammation, making it a promising choice for skin breakouts. In addition, this combination was not toxic to fibroblasts, supporting its capacity as a safe skin treatment. Interestingly, at a 15:5:10 GM:CC:AE ratio, this combination treatment displayed high selectivity indices (SIs) against Staphylococcus epidermidis (26.87) and C. acnes (4.99), indicating its strong therapeutic potential without side effects. In conclusion, our study highlights that this combination is a novel, effective, and safe choice for controlling acne vulgaris, especially because of its ability to inhibit TOP2α and regulate NFκB1.

19 August 2026 in Life
Verified
Journal Article
Open access
PDF file
ATAman Tedasen
Aman Tedasen
SRSiriwimon Ranjuanjit
Siriwimon Ranjuanjit
NSNattacha Srirod
Nattacha Srirod
KBKingkan Bunluepeuch
Kingkan Bunluepeuch
Maria de Lourdes PereiraMaria de Lourdes Pereira
Maria de Lourdes Pereira
Orawan SarakulOrawan Sarakul
Orawan Sarakul
Background/Objectives: Oxidative stress is a major cause of RBC membrane damage, especially in individuals with G6PD deficiency who have impaired antioxidant defenses. Triphala, a phenolic-rich herbal formulation with known antioxidant activity, was evaluated for its phytochemical profile, antioxidant and anti-hemolytic effects, and molecular mechanisms in H2O2-induced oxidative stress models using normal and G6PD-deficient human RBCs. Methods: Triphala aqueous extract was characterized using LC-MS and GC-MS. Antioxidant activity was evaluated by DPPH and ABTS assays. Cytotoxicity, membrane stability, and protection against H2O2-induced hemolysis were assessed in normal and G6PD-deficient RBCs. Network pharmacology, molecular docking and MD simulation analyses were performed to predict antioxidant-related mechanisms. Statistical analysis was conducted using one-way ANOVA (p < 0.05). Results: LC-MS identified gallic acid as the predominant phenolic compound, while GC-MS revealed pyrogallol as the major constituent. The extract showed strong radical scavenging activity and significantly reduced H2O2-induced hemolysis in both normal and G6PD-deficient RBCs without cytotoxicity (p < 0.05). Network pharmacology revealed that G6PD-related antioxidant regulation, oxidative stress response, and inflammatory signaling pathways are the key enriched biological processes. Network pharmacology analysis ranked PPARG, PTGS2, EGFR, MMP9, TLR4, ACE, REN, PPARA, SERPINE1, and MMP2 as the top hub proteins, highlighting their central roles in oxidative stress, inflammation, and metabolic signaling pathways. Kynurenic acid binds strongly to PTGS2 (COX-2) and ACE with binding affinities below −7.0 kcal/mol, forming multiple hydrogen bonds that stabilize its interactions within the active sites. MD simulations confirmed that kynurenic acid binds stably to ACE and PTGS2, with RMSD values plateauing near 2.4 Å and 3.0 Å, RMSF values mostly below 2 Å, and recurrent hydrogen bonding and electrostatic contacts with key residues, collectively underscoring its conformational stability, adaptive flexibility, and modulatory potential. Conclusions: Triphala aqueous extract exhibits potent antioxidant and anti-hemolytic activities and may serve as a natural adjunct strategy for reducing oxidative damage in G6PD deficiency and related RBC disorders.